← Evidence map

ArticleJapanese journal of ophthalmology2023

Correction to: Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.

Ryusaburo Mori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Correction to: Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial. | OpenQuestion